{
  "paper_id": "PMC8720292",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720292/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Nanoparticles must overcome multiple barriers for effective gene therapy to the brain. Particles may be administered systemically, after which stability in circulation and extravasation past the BBB into the brain must be optimized, or locally directly at the tumor site in the brain. Once in the brain, nanoparticles must distribute sufficiently throughout the tumor tissue and be taken up by target cells, which may be either tumor cells or surrounding cell types that contribute to tumor growth. This targeting may be accomplished by transfecting tumor-homing cells or by functionalizing the nanoparticles with ligands for receptors on the target cells.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/1fcb78d9799f/nihms-1752786-f0001.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/1fcb78d9799f/nihms-1752786-f0001.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/1fcb78d9799f/nihms-1752786-f0001.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/1fcb78d9799f/nihms-1752786-f0001.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/1fcb78d9799f/nihms-1752786-f0001.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8720292/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/1fcb78d9799f/nihms-1752786-f0001.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Polymer-based nanocapsules carrying siRNA were functionalized with angiopep-2 [Ang-NCss(siRNA)] for efficient BBB crossing and specific targeting of brain tumor cells. The crosslinks within the nanocapsules contained disulfide bonds for triggered cytosolic siRNA release. Reprinted with permission from Y. Zou, X. Sun, Y. Wang, C. Yan, Y. Liu, J. Li, D. Zhang, M. Zheng, R.S. Chung, B. Shi, Single siRNA Nanocapsules for Effective siRNA Brain Delivery and Glioblastoma Treatment, Adv. Mater. 32 (2020) [78]. Copyright (2020) John Wiley & Sons, Inc.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/290ca5b8f929/nihms-1752786-f0002.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/290ca5b8f929/nihms-1752786-f0002.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/290ca5b8f929/nihms-1752786-f0002.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/290ca5b8f929/nihms-1752786-f0002.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/290ca5b8f929/nihms-1752786-f0002.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8720292/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/290ca5b8f929/nihms-1752786-f0002.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "Retro-inverso CendR peptide-functionalized PEG-PEI particles were used to deliver DsRed DNA. DsRed signal in the brain is higher in functionalized particles than in mPEG-PEI particles, measured by fluorescence imaging of the whole brain (A) and fluorescence microscopy on brain sections (B). Reprinted with permission from J. Wang, Y. Lei, C. Xie, W. Lu, E. Wagner, Z. Xie, J. Gao, X. Zhang, Z. Yan, M. Liu, Retro-inverso CendR peptide-mediated polyethyleneimine for intracranial glioblastoma-targeting gene therapy, Bioconjug. Chem. 25 (2014) 414–423 [94]. Copyright (2014) American Chemical Society.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/ad3ea80341a6/nihms-1752786-f0003.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/ad3ea80341a6/nihms-1752786-f0003.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/ad3ea80341a6/nihms-1752786-f0003.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/ad3ea80341a6/nihms-1752786-f0003.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/ad3ea80341a6/nihms-1752786-f0003.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8720292/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/ad3ea80341a6/nihms-1752786-f0003.jpg"
    },
    "figure_4": {
      "figure_number": "Figure 4",
      "title": "Figure 4.",
      "caption": "(A) The Vir-Gel is made by crosslinking DNA-grafted PCL with miRNA to form a nanogel, then coating the nanoparticles with erythrocyte membranes and functionalizing with M2 microglia-targeting and membrane fusion-promoting peptides. (B) The functionalized particles reprogram the microglia at the glioma site after administration, resulting in an anti-tumor immune response. Reprinted with permission from X. Gao, S. Li, F. Ding, X. Liu, Y. Wu, J. Li, J. Feng, X. Zhu, C. Zhang, A Virus-Mimicking Nucleic Acid Nanogel Reprograms Microglia and Macrophages for Glioblastoma Therapy, Adv. Mater. 33 (2021) [100]. Copyright (2021) John Wiley & Sons, Inc.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/6f84612052c5/nihms-1752786-f0004.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/6f84612052c5/nihms-1752786-f0004.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/6f84612052c5/nihms-1752786-f0004.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/6f84612052c5/nihms-1752786-f0004.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F4",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/6f84612052c5/nihms-1752786-f0004.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8720292/images/figure_4.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/6f84612052c5/nihms-1752786-f0004.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Figure 5.",
      "caption": "(A) The bioreducible nanoparticle formulation (nano-miR) labeled with the fluorescent dye Dy547 was visualized and compared to adjacent H&E-stained sections. The intratumoral distribution of the nano-miRs was about 60% (right panel). (B) Schematic summarizing treatment schedule for the in vivo delivery of nano-miRs. Animals were sacrificed 42 days after cell implantation to quantify maximum tumor cross-sectional areas showing significantly lower (C) viable tumor areas and (D) higher necrotic areas for animals treated with nano-miRs compared to controls (Ctrl.). (E) miR-148a and miR-296-5p co-delivery using nano-miRs (miR-Comb.) extended the survival compared to mice treated with control nano-miRs (miR-Ctrl). Reprinted with permission from H. Lopez-Bertoni, K.L. Kozielski, Y. Rui, B. Lal, H. Vaughan, D.R. Wilson, N. Mihelson, C.G. Eberhart, J. Laterra, J.J. Green, Bioreducible Polymeric Nanoparticles Containing Multiplexed Cancer Stem Cell Regulating miRNAs Inhibit Glioblastoma Growth and Prolong Survival, Nano Letters, 18 (2018) 4086–4094 [118]. Copyright (2018) American Chemical Society.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/a43ee4b0f04a/nihms-1752786-f0005.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/a43ee4b0f04a/nihms-1752786-f0005.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/a43ee4b0f04a/nihms-1752786-f0005.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/a43ee4b0f04a/nihms-1752786-f0005.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F5",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/a43ee4b0f04a/nihms-1752786-f0005.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8720292/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/a43ee4b0f04a/nihms-1752786-f0005.jpg"
    },
    "figure_6": {
      "figure_number": "Figure 6",
      "title": "Figure 6.",
      "caption": "(A-B) Quantum dots were loaded with siRNA targeting EGFRvIII via a disulfide linkage and functionalized with ligands to improve uptake and membrane fusion. (C) The reducible disulfide bridge promotes quick cytosolic release of siRNA, and other linkages can also be used to functionalize the siRNA for intracellular tracking. Reproduced with permission from J. Jung, A. Solanki, K.A. Memoli, K.I. Kamei, H. Kim, M.A. Drahl, L.J. Williams, H.R. Tseng, K. Lee, Selective inhibition of human brain tumor cells through multifunctional quantum-dot-based siRNA delivery, Angew. Chemie. Int. Ed. 49 (2010) 103–107 [147]. Copyright 2010 John Wiley & Sons, Inc.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/e9821293a266/nihms-1752786-f0006.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/e9821293a266/nihms-1752786-f0006.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/e9821293a266/nihms-1752786-f0006.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/e9821293a266/nihms-1752786-f0006.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F6",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/e9821293a266/nihms-1752786-f0006.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8720292/images/figure_6.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/e9821293a266/nihms-1752786-f0006.jpg"
    },
    "figure_7": {
      "figure_number": "Figure 7",
      "title": "Figure 7.",
      "caption": "GBM cells were injected intracranially into mice, and ADSCs were transfected ex vivo with TRAIL using PBAE-based nanoparticles, then administered to tumor-bearing mice (A). Mice treated with TRAIL nanoparticles fared better, measured by body weight (B), tumor size (C-D), and survival time (E). A single injection of transfected ADSCs had significant survival benefit, but additional dosing also significantly extended median survival. Reproduced with permission from X. Jiang, S. Fitch, C. Wang, C. Wilson, J. Li, G.A. Grant, F. Yang, Nanoparticle engineered TRAIL-overexpressing adipose-derived stem cells target and eradicate glioblastoma via intracranial delivery, Proc. Natl. Acad. Sci. U. S. A. 113 (2016) 13857–13862 [185].",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/006f561ddde4/nihms-1752786-f0007.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/006f561ddde4/nihms-1752786-f0007.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/006f561ddde4/nihms-1752786-f0007.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/006f561ddde4/nihms-1752786-f0007.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "F7",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/006f561ddde4/nihms-1752786-f0007.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC8720292/images/figure_7.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e4c6/8720292/006f561ddde4/nihms-1752786-f0007.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Key hurdles associated with therapeutic design and delivery include BBB permeability, formulation stability, cancer cell targeting and specificity, cellular uptake, and safety considerations (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "These nanocapsules were then functionalized with Ang, and the authors termed the formed particles Ang-NCss(siRNA) being approximately 25 nm (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "A retro-inverso CendR peptide, which contains d-amino acids in reverse order from the original l-amino acid sequence and is resistant to proteolysis, also showed neuropilin-1 binding and enhanced U87 transfection with DNA compared with unconjugated PEG-PEI nanoparticles (Figure 3) [94].",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "These were then coated with erythrocyte membranes and functionalized with M2pep, which targets M2-type macrophages and microglia, and the HA2 peptide, which promotes membrane fusion (Figure 4).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "The engineered bioreducible nanoparticles delivering miRNA were found to be distributed through approximately 60% of brain tumor volume (Figure 5) [118].",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "Their delivery platform incorporated multiple mechanisms of targeting, including an RGD signal to improve uptake by U87 cells, an HIV-Tat peptide to improve membrane fusion for uptake and endosomal escape, and reducible linkages for quick cytosolic release of siRNA [147] (Figure 6).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "By combining the targeting capacities of ADSC homing and TRAIL cancer-specificity, the authors were able to demonstrate apoptosis in the main tumor and microsatellites but not in healthy normal brain parenchyma, and this led to significantly longer survival in mice bearing a patient-derived GBM xenograft (Figure 7) [185].",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "",
          "figure_key": "figure_7"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 7,
    "claims_count": 77,
    "images_downloaded": 7,
    "tables_filtered": 16
  }
}